Auxilium Pharmaceuticals Announces Positive Data from Commercial Patient Chart Review in E-posters at ASSH Meeting
MALVERN, Pa., Sept. 8, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that positive data from a retrospective commercial patient chart review of XIAFLEX® (collagenase clostridium histolyticum) used for the treatment of adult Dupuytren's contracture patients with a palpable cord are available via e-posters at the American Society for Surgery of the Hand meeting in Las Vegas. In the chart review, 292 patients who received commercial XIAFLEX were followed to determine if real-world use of XIAFLEX resulted in improved outcomes versus results that were reported in the U.S. pivotal phase III double-blind placebo controlled trial of XIAFLEX (CORD I) (1). Although there are limitations in comparing separate studies head to head, results from the retrospective patient chart review indicated that fewer injections resulted in improved outcomes with XIAFLEX versus reported outcomes from CORD I.
"These results indicate that trained physicians who are using XIAFLEX in real-world conditions should be able to achieve better outcomes than the clinical trials with less XIAFLEX," said Dr. Gary Pess of Central Jersey Hand Surgery. "I believe that first-line non-surgical treatment of Dupuytren's patients' palpable cords with XIAFLEX may allow treatment before a patient would be eligible for surgery and can provide durable outcomes with a low rate of recurrence in the majority of patients."
In abstract 21, the retrospective chart review results indicate that real-world use of XIAFLEX resulted in a higher percentage of patients who achieved release after the first injection than was reported in CORD I, potentially due to use of a